UAE Pharmaceutical Manufacturing 2026: Market and Investment Outlook

The UAE pharmaceutical sector is entering a period of increased investment, regulatory development and localisation. The country already functions as an important healthcare and pharmaceutical distribution centre for the Middle East, while government policy is increasingly focused on building domestic manufacturing capacity and strengthening security of supply.

For investors considering a pharmaceutical manufacturing facility, however, the underlying opportunity should be assessed with some caution. A growing market and supportive industrial policy do not by themselves establish the viability of a manufacturing project. The commercial case ultimately depends on the products selected, addressable demand, regulatory pathway, manufacturing economics, capacity utilisation and the ability to compete with established local and international suppliers.

Market outlook

The UAE pharmaceutical market is estimated at approximately USD 4.99 billion in 2026, compared with USD 4.45 billion in 2025. Current industry forecasts place the market at approximately USD 8.59 billion by 2034, representing a compound annual growth rate of around 7.0% between 2026 and 2034.

These figures indicate an attractive medium-term demand environment, although they represent third-party market estimates rather than official government forecasts.

The underlying market remains predominantly supplied by imported products. The U.S. International Trade Administration describes the UAE as currently importing most of its pharmaceutical requirements, while noting the increasing development of local manufacturing partnerships.

This is an important consideration for potential manufacturers. Import dependence creates opportunities for localisation, particularly where domestic production can improve availability, supply security or procurement economics. At the same time, imported products from established multinational and regional manufacturers create strong competition on price, quality and brand recognition.

Accordingly, the opportunity should not be assessed on the basis of import substitution alone. Investors should identify product categories where there is a demonstrable commercial or strategic case for local manufacturing.

Selected market indicators

The GCC generic injectables market is separately estimated at approximately USD 842.4 million in 2025 and forecast to reach approximately USD 2.01 billion by 2034, implying growth of approximately 9.9% annually. This is particularly relevant to investors evaluating injectable, vial and pre-filled syringe manufacturing, although the forecast should be considered alongside product-specific demand analysis.

Local manufacturing is becoming a strategic priority

The policy direction towards greater pharmaceutical localisation is now clearer than it was several years ago.

The Emirates Drug Establishment has identified the development of domestic pharmaceutical manufacturing as part of its strategic agenda. Its Holistic National Manufacturing project is intended to build a broader national production base covering advanced medicines and human, veterinary and agricultural medical products.

During Make it in the Emirates 2026, the EDE also highlighted the development of a broader life-sciences ecosystem extending beyond traditional pharmaceutical manufacturing into diagnostics, biotechnology and advanced therapies. It specifically referred to strengthening local manufacturing through investment and technology transfer.

This direction should be viewed as strategically supportive rather than as a guarantee of commercial success. Local manufacturers will still need to demonstrate competitive product economics, regulatory compliance and sustainable market access.

Supply-chain resilience strengthens the localisation case

Recent UAE industrial policy has placed greater emphasis on resilience of critical supply chains, including medical products.

In April 2026, the UAE Cabinet approved a National Industrial Resilience Fund of AED 1 billion and measures aimed at expanding local production and reducing vulnerability in strategically important supply chains.

A separate national supply-chain resilience programme explicitly includes medical goods among the categories for which the UAE intends to strengthen security of supply through diversified sourcing and increased domestic production.

For pharmaceutical investors, this provides a favourable strategic backdrop. The commercial significance, however, will differ substantially by therapeutic category. Products classified as essential, difficult to source or strategically important may have a stronger localisation rationale than products already supplied competitively by multiple international manufacturers.

Government procurement and In-Country Value

The UAE's procurement environment can also favour businesses that establish meaningful local economic activity, although this should not be interpreted as an automatic purchase guarantee for locally manufactured pharmaceutical products.

In 2026, the UAE made the National In-Country Value programme mandatory across selected government entities and companies in which the government holds at least 25%. The policy is intended, among other objectives, to direct institutional demand towards priority national products and strengthen local supply chains.

The healthcare sector had already begun incorporating ICV considerations into procurement. The Department of Health – Abu Dhabi, Rafed and PureHealth joined the programme in 2023, allowing ICV scoring to be used as a preferential factor in procurement of goods and services.

Historically, GCC government procurement rules have also provided preferential treatment to national and GCC-produced goods, including a 10% price preference relative to foreign products under the relevant framework.

For a new pharmaceutical manufacturer, these mechanisms can strengthen the commercial case for local production, but their actual impact should be evaluated product by product and tender by tender. ICV scoring, product registration, pricing, clinical acceptance and supplier qualification will generally matter alongside manufacturing origin.

Access to the wider GCC market

The UAE can also provide a manufacturing base from which GCC markets may be served.

Under the GCC Customs Union framework, goods produced within a GCC member state are generally accorded national treatment and may move between member states under the applicable customs framework.

This is more precise than simply saying that all UAE-manufactured pharmaceuticals are automatically “duty-free across the GCC”. Pharmaceutical products remain subject to regulatory registration, rules of origin, customs documentation and market-specific requirements.

The regional opportunity therefore exists, but an investor should model the UAE and each export market separately rather than assuming unrestricted regional access.

The UAE manufacturing base is expanding

Publicly available information confirms an expanding pharmaceutical manufacturing ecosystem.

The Emirates Drug Establishment maintains a dedicated register of licensed pharmaceutical facilities and a national database of registered medical products. Its registered-product directory contained more than 17,000 entries as of October 2026, covering domestic and international manufacturers and various medical-product classifications.

The EDE reported in February 2026 that it had licensed 37 facilities for the production of human pharmaceutical and medical products. Industry research similarly reports more than 35 pharmaceutical manufacturing facilities operating in the UAE, although different sources use different definitions of pharmaceutical factories and medical-product manufacturing facilities. For this reason, the industry figure should be treated as an estimate, with the EDE count used as the regulatory reference point.

More important than the absolute number of factories is the evolution of the manufacturing mix. The UAE is increasingly looking beyond conventional oral dosage forms towards areas such as:

• sterile injectables;
• biologics and biosimilars;
• oncology products;
• advanced therapies;
• diagnostics;
• specialised formulations; and
• biotechnology.

This direction potentially creates opportunities for differentiated manufacturers, but also raises the technical and regulatory threshold for new entrants.

Regulation and licensing

A pharmaceutical manufacturing facility requires significantly more than a normal industrial or commercial licence.

The Emirates Drug Establishment's current licensing process includes:

1. initial approval for the manufacturing facility;
2. approval of engineering plans;
3. construction and fit-out;
4. initial GMP assessment;
5. evaluation of qualified personnel;
6. GMP inspection;
7. issuance of a Good Manufacturing Practice compliance certificate; and
8. final manufacturing-facility licensing.

The EDE publishes service-level processing periods for individual regulatory steps. For example, initial approval is stated as five working days, assignment of the GMP audit team as ten days, issuance of the GMP compliance certificate as five working days after the inspection report, and final licensing as three working days once all requirements are completed.

These periods should not be interpreted as the development period for an entire pharmaceutical factory. Construction, cleanroom installation, equipment procurement, commissioning, qualification, validation, recruitment and product registration can collectively take substantially longer and depend heavily on the complexity of the facility.

For this reason, a universal “2.5 to 3 year” construction and launch period should not be presented as an established UAE benchmark. A detailed project implementation schedule should instead be developed for the individual facility.

For pharmaceutical products themselves, EDE currently publishes a service completion period of 45 working days for the marketing-authorisation process, once a compliant application has been submitted. However, the process may also require stability, bioequivalence, pharmacovigilance and laboratory analysis depending on the product.

Again, this service period should not be confused with the complete product-development and registration timeline.

Site selection should follow the manufacturing strategy

Investors often begin with the question of which free zone or emirate offers the lowest land cost. For pharmaceutical manufacturing, this should normally come later.

The preferred location should be determined by:

• manufacturing process;
• cleanroom requirements;
• electricity demand;
• water and clean-utility requirements;
• hazardous-material and waste-management requirements;
• logistics;
• availability of specialist labour;
• proximity to hospitals, distributors or export infrastructure;
• expansion potential;
• land tenure;
• customs implications; and
• financing requirements.

The relevant comparison is therefore total project economics, not simply rental cost per square metre.

The commercial case must be product-specific

The strongest feasibility studies do not calculate revenue by taking a small percentage of the total UAE pharmaceutical market.

Demand should instead be built from the commercial drivers of each product.

For physician-led products, an appropriate framework may include:

target physicians × expected adoption × patients per physician × treatment frequency × units per treatment × realised selling price

For hospital or institutional products, the model may instead consider:

addressable hospitals × procedure volume × product utilisation × tender penetration × realised tender price

For export markets, registration timing, distributor margins, logistics and country-specific pricing should be incorporated separately.

This bottom-up approach provides a much more defensible basis for investment decisions than applying an assumed market share to an industry-level market forecast.

Capacity utilisation is one of the key investment variables

Pharmaceutical manufacturing is characterised by relatively high fixed costs. Cleanrooms, quality-control laboratories, engineering support, regulatory personnel and specialist production staff have to be maintained even when utilisation is low.

A feasibility study should therefore distinguish between:

• theoretical line capacity;
• practical operating capacity;
• batch-changeover time;
• maintenance downtime;
• validation and cleaning periods;
• production yields;
• rejected batches; and
• expected utilisation during ramp-up.

The key question is not simply whether the factory can manufacture a product.

It is whether sufficient volumes can be sold to operate the facility economically.

CAPEX should cover the complete pharmaceutical facility

Headline machinery prices can materially understate the investment required.

A complete capital budget should separately identify:

• land and site development;
• civil works;
• GMP finishes;
• cleanrooms;
• HVAC;
• purified water and clean utilities;
• production machinery;
• filling and packaging lines;
• warehousing;
• laboratories;
• quality-control equipment;
• IT and pharmaceutical quality systems;
• commissioning;
• qualification and validation;
• regulatory costs;
• pre-operating expenditure; and
• appropriate project contingency.

A feasibility study should also distinguish between equipment quotations and assumptions so that investors can see clearly where cost uncertainty remains.

Working capital can be significant

Pharmaceutical manufacturing can require substantial working capital even where accounting margins appear attractive.

Cash may be tied up in:

• APIs and other imported raw materials;
• packaging components;
• work in progress;
• laboratory testing;
• quarantine inventory;
• finished goods;
• safety stock; and
• customer receivables.

This can become particularly important where raw materials are paid for relatively quickly while hospitals, distributors or institutional customers operate on longer settlement periods.

Working capital should therefore be included in the initial funding requirement rather than treated solely as a post-launch operating issue.

Financing is available, but bankability remains critical

The UAE has dedicated development-financing capacity for manufacturing and healthcare.

Emirates Development Bank identifies manufacturing and healthcare among its five priority sectors and specifically includes pharmaceutical industries and biotechnology within its healthcare mandate.

EDB offers long-term CAPEX finance as well as greenfield and brownfield project financing, together with working-capital solutions for manufacturers.

Its broader industrial mandate includes AED 30 billion of financing support for priority sectors.

The existence of development financing should nevertheless not be interpreted as assurance that a project will qualify. Lenders will still assess sponsor strength, technical feasibility, equity contribution, cash-flow generation, collateral, execution risks and debt-service capacity.

For a greenfield pharmaceutical project, the feasibility study therefore becomes an important part of both the investment and financing process.

Corporate tax and free-zone considerations

The standard UAE corporate tax regime currently applies:

• 0% on taxable income up to AED 375,000; and
• 9% on taxable income above AED 375,000.

A Qualifying Free Zone Person may benefit from a 0% corporate tax rate on Qualifying Income, while taxable income that does not qualify is subject to 9%.

The 0% free-zone rate should therefore not be assumed automatically in a pharmaceutical feasibility model.

The entity's activities, customers, transactions, substance and compliance with the Qualifying Free Zone Person requirements need to be assessed before determining the appropriate tax treatment.

Overall investment perspective

The UAE presents a credible and increasingly sophisticated environment for pharmaceutical manufacturing.

The investment case is supported by several observable factors:

• a pharmaceutical market estimated at approximately USD 5 billion and forecast to continue growing;
• continuing dependence on imported medicines;
• explicit government policy supporting pharmaceutical localisation;
• greater emphasis on medical supply-chain resilience;
• ICV and procurement policies that can support local economic activity;
• established logistics infrastructure and access to wider GCC markets;
• development financing available to manufacturing and healthcare businesses; and
• a regulatory framework increasingly focused on pharmaceutical manufacturing and innovation.

These factors are positive, but they do not eliminate the underlying investment risks.

A greenfield pharmaceutical facility remains a capital-intensive and highly regulated project. Returns can be sensitive to regulatory delays, slower-than-expected sales adoption, pricing pressure, underutilised capacity, imported input costs and working-capital requirements.

The investment decision should therefore be based on a product-level commercial case and an integrated technical and financial feasibility study, rather than on industry growth alone.

In practical terms, four questions should drive the decision:

• Is there sufficient addressable demand for the selected products?
• Can the products be manufactured at a competitive cost while meeting the required regulatory and quality standards?
• Can the facility achieve sufficient utilisation within a reasonable ramp-up period?
• Do the resulting cash flows provide an acceptable return relative to the capital invested and the risks assumed?

Where these questions can be demonstrated with credible evidence, the UAE can offer a strong platform for pharmaceutical manufacturing. Where they cannot, government incentives or overall market growth are unlikely on their own to make the investment viable.

How Baker Tilly UAE can assist

Baker Tilly UAE can support investors in independently assessing the commercial and financial viability of a proposed pharmaceutical project, including market and demand assessment, feasibility studies, integrated financial modelling, CAPEX and operating-cost review, funding and working-capital analysis, tax and structuring, scenario and sensitivity analysis, and lender or investor support. The objective is to provide sponsors, boards and financing institutions with an evidence-based view of the project's potential returns, funding requirements and principal risks before significant capital is committed.

1. ^

    IMARC Group, “UAE Pharmaceutical Market Size, Share & Forecast 2034” (2026): USD 4.45 billion (2025), USD 4.99 billion (2026), USD 8.59 billion (2034), CAGR 7.01% (2026–2034). https://www.imarcgroup.com/uae-pharmaceutical-market. For comparison, Grand View Research estimates USD 5.0 billion (2025) and USD 8.0 billion by 2033: https://www.grandviewresearch.com/horizon/outlook/pharmaceutical-market/uae

2. ^

    U.S. International Trade Administration, “Healthcare Resource Guide – United Arab Emirates”. https://www.trade.gov/healthcare-resource-guide-united-arab-emirates

3. ^

    IMARC Group, “GCC Generic Injectables Market Size, Share, Report 2034”: USD 842.4 million (2025), USD 2,013.4 million (2034), CAGR 9.86% (2026–2034). https://www.imarcgroup.com/gcc-generic-injectables-market

4. ^

    Gulf Business, “WHX 2026: Emirates Drug Establishment launches key pharma initiative” (February 2026). https://gulfbusiness.com/emirates-drug-establishment-launches-at-whx-2026/

5. ^

    Zawya / EDE press release, “Emirates Drug Establishment concludes participation in Make it in the Emirates 2026” (8 May 2026). https://www.zawya.com/en/press-release/events-and-conferences/emirates-drug-establishment-concludes-participation-in-make-it-in-the-emirates-2026-tmtn8fb1

6. ^

    UAE Cabinet, “Mohammed bin Rashid approves decisions to enhance industrial resilience, support national products” (26 April 2026). https://uaecabinet.ae/en/news/mohammed-bin-rashid-approves-decisions-to-enhance-industrial-resilience-support-national-products

7. ^

    WAM, “Mohammed bin Rashid approves launch of National Programme to Strengthen Supply Chain Resilience in UAE” (29 April 2026). https://www.wam.ae/en/article/bzyl9u3-mohammed-bin-rashid-approves-launch-national

8. ^

    Economy Middle East, “UAE Cabinet approves $272.3 million Industrial Resilience Fund, new localization measures” (27 April 2026). https://economymiddleeast.com/news/uae-cabinet-approves-272-3-million-industrial-resilience-fund-new-localization-measures/

9. ^

    Ministry of Industry and Advanced Technology, “Department of Health Abu Dhabi, Rafed and Pure Health join The National In Country Value program” (27 March 2023). https://moiat.gov.ae/en/media-center/news/2023/03/27/icv-mou-with-doh-rafed-and-purehealth

10. ^

     See, e.g., GCC–Singapore Free Trade Agreement, Chapter 6 (Government Procurement), Article 6.7 (10% price preference for domestically produced goods by GCC Member States). https://www.enterprisesg.gov.sg/-/media/esg/files/non-financial-assistance/for-companies/free-trade-agreements/GSFTA/Legal_text/Chapter_6_Government_Procurement. The current application of this preference in UAE procurement should be confirmed tender by tender.

11. ^

     Federal Authority for Identity, Citizenship, Customs and Port Security, “Customs Union for GCC States”. https://icp.gov.ae/en/customs-union-for-gcc/

12. ^

     Emirates Drug Establishment, Registered Medical Product Directory (17,164 entries; dataset refreshed 4 August 2026). https://services.ede.gov.ae/drugdirectory?lang=en-US. See also Emirates 24|7, “UAE-made medical products lead national register as total approved products exceed 17,000”. https://www.emirates247.com/business/uae-made-medical-products-lead-national-register-as-total-approved-products-exceed-17000/3384

13. ^

     Gulf News, “UAE ramps up local medicine manufacturing with launch of Emirates Drug Establishment” (February 2026). https://gulfnews.com/uae/uae-ramps-up-local-medicine-manufacturing-with-launch-of-emirates-drug-establishment-1.500437470. Industry estimate of over 35 factories: IMARC Group, https://www.imarcgroup.com/uae-pharmaceutical-market

14. ^

     Emirates Drug Establishment, “Licensing of a Pharmaceutical Facility” (service guide). https://www.ede.gov.ae/documents/61005/62137/Licensing+of+a+Pharmaceutical+Facility.pdf

15. ^

     Emirates Drug Establishment, “Issuance of Marketing Authorization for a Drug or Biopharmaceutical Product” (service completion duration: 45 working days). https://www.ede.gov.ae/en/w/issuance-of-marketing-authorization-for-a-drug-or-biopharmaceutical-product

16. ^

     Emirates Development Bank, “Emirates Development Bank reveals commitment to financing UAE renewables sector” (priority sectors). https://edb.gov.ae/posts/emirates-development-bank-reveals-commitment-to-financing-uae-renewables-sector

17. ^

     Emirates Development Bank, “EDB unveils AED362 million financing deals…” (28 May 2024): AED 30 billion portfolio to support priority industrial sectors by 2026. https://edb.gov.ae/posts/edb-unveils-aed362-million-financing-deals-increasing-its-financing-volumes-for-manufacturing-to-a-fresh-record-of-aed54-billion-ytd-2024

18. ^

     Federal Tax Authority, Corporate Tax Guide – Free Zone Persons (CTGFZP1). Note that a Qualifying Free Zone Person does not benefit from the 0% rate on the first AED 375,000 of taxable income. https://tax.gov.ae/Datafolder/Files/Guides/CT/Free%20Zone%20Persons%20-%2020%2005%202024%20final%20for%20GCD.pdf